Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Gracell Biotechnologies

Main focus: Next generation CAR-T

Company stage: Clinical

Diseases: Adult T-cell acute lymphoblastic leukaemia (T ALL), others undisclosed

Genome editing technology: CRISPR-Cas9

Funding stage: Public (NASDAQ:GRCL)

Location: Suzhou, China and Palo Alto, CA, USA



Gracell Biotechnologies is a clinical-stage CAR-T focused company. Its pipeline is derived from two proprietary technology platforms: the FasTCAR and TruUCAR platforms. FasTCAR is an autologous-based platform that allows for improved manufacturing speed and quality as well as improved T-cell fitness. TruUCAR is an allogeneic, off-the-shelf-based platform. Here, CRISPR-Cas9 is used to knock out the T cell receptor (TCR) and specific tumour antigens in allogeneic CAR-T products. One TruUCAR-based programme has so far entered a clinical trial.


HashtagGracell Biotechnologies Co., Ltd

Company: Gracell Biotechnologies
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine